Cholinergic-serotonergic imbalance contributes to cognitive and behavioral symptoms in Alzheimer's disease

被引:198
作者
Garcia-Alloza, M.
Gil-Bea, F. J.
Diez-Ariza, M.
Chen, C. P. L. -H.
Francis, P. T.
Lasheras, B.
Ramirez, M. J.
机构
[1] Univ Navarra, Sch Med, Dept Pharmacol, Pamplona 31008, Spain
[2] Singapore Gen Hosp, Natl Neurosci Inst, Dept Neurol, Singapore 169608, Singapore
[3] Kings Coll London, GKT Sch Biomed Sci, Ctr Neurosci Res, Dementia Res Lab, London, England
关键词
cognitive decline; behavioral and psychological syndromes of dementia (BPSD); cholineacetyltransferase; 5-HT; cortex; human;
D O I
10.1016/j.neuropsychologia.2004.06.007
中图分类号
B84 [心理学]; C [社会科学总论]; Q98 [人类学];
学科分类号
03 ; 0303 ; 030303 ; 04 ; 0402 ;
摘要
Neuropsychiatric symptoms seen in Alzheimer's disease (AD) are not simply a consequence of neurodegeneration, but probably result from differential neurotransmitter alterations, which some patients are more at risk. of than others. Therefore, the hypothesis of this study is that an imbalance between the cholinergic and serotonergic systems is related to cognitive symptoms and psychological syndromes of dementia (BPSD) in patients with AD. Cholinergic and serotonergic functions were assessed in post-mortem frontal and temporal cortex from 22 AD patients who had been prospectively assessed with the Mini-Mental State examination (MMSE) for cognitive impairment and with the Present Behavioral Examination (PBE) for BPSD including aggressive behavior, overactivity, depression and psychosis. Not only cholinergic deficits, but also the cholinacetyltransferase/serotonin ratio significantly correlated with final MMSE score both in frontal and temporal cortex. In addition, decreases in cholinergic function correlated with the aggressive behavior factor, supporting a dual role for the cholinergic system in cognitive and non-cognitive disturbances associated to AD. The serotonergic system showed a significant correlation with overactivity and psychosis. The ratio of serotonin to acetylcholinesterase levels was also correlated with the psychotic factor at least in women. It is concluded that an imbalance between cholinergic-serotonergic systems may be responsible for the cognitive impairment associated to AD. Moreover, the major findings of this study are the relationships between neurochemical markers of both cholinergic and serotonergic systems and non-cognitive behavioral disturbances in patients with dementia. (c) 2004 Elsevier Ltd. All rights reserved.
引用
收藏
页码:442 / 449
页数:8
相关论文
共 50 条
  • [1] [Anonymous], 1987, DIAGNOSTIC STAT MANU, V4th
  • [2] Gene expression profiling in the post-mortem human brain - no cause for dismay
    Bahn, S
    Augood, S
    Standaert, DG
    Starkey, M
    Emson, PC
    [J]. JOURNAL OF CHEMICAL NEUROANATOMY, 2001, 22 (1-2) : 79 - 94
  • [3] Role of serotonin in memory impairment
    Buhot, HC
    Martin, S
    Segu, L
    [J]. ANNALS OF MEDICINE, 2000, 32 (03) : 210 - 221
  • [4] Antipsychotic medications and the elderly - Effects on cognition and implications for use
    Byerly, MJ
    Weber, MT
    Brooks, DL
    Snow, LR
    Worley, MA
    Lescouflair, E
    [J]. DRUGS & AGING, 2001, 18 (01) : 45 - 61
  • [5] Presynaptic serotonergic markers in community-acquired cases of Alzheimer's disease: Correlations with depression and neuroleptic medication
    Chen, CPLH
    Alder, JT
    Bowen, DM
    Esiri, MM
    McDonald, B
    Hope, T
    Jobst, KA
    Francis, PT
    [J]. JOURNAL OF NEUROCHEMISTRY, 1996, 66 (04) : 1592 - 1598
  • [6] Chen Z, 2000, MICROW OPT TECHN LET, V26, P1, DOI 10.1002/(SICI)1098-2760(20000705)26:1<1::AID-MOP1>3.0.CO
  • [7] 2-E
  • [8] Neuropsychiatric aspects of Alzheimer's disease: The cholinergic hypothesis revisited
    Cummings, JL
    Kaufer, D
    [J]. NEUROLOGY, 1996, 47 (04) : 876 - 883
  • [9] The NMDA receptor antagonist memantine as a symptomatological and neuroprotective treatment for Alzheimer's disease: preclinical evidence
    Danysz, W
    Parsons, CG
    [J]. INTERNATIONAL JOURNAL OF GERIATRIC PSYCHIATRY, 2003, 18 : S23 - S32
  • [10] Antipsychotic agents in patients with dementia
    Defilippi, JL
    Crismon, ML
    [J]. PHARMACOTHERAPY, 2000, 20 (01): : 23 - 33